|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 701 PENNSYLVANIA AVENUE, NW |
Address2 | SUITE 720 |
City | WASHINGTON |
State | DC |
Zip Code | 20004 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 9237-12
|
||||||||
|
6. House ID# 316700000
|
TYPE OF REPORT | 8. Year | 2021 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Kristin Julason Damato |
Date | 7/20/2021 4:49:18 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
* H.R 2166/S. 150, Ensuring Parity in MA for Audio-Only Telehealth Act of 2020, to amend title XVIII of the Social Security Act to require the inclusion of certain audio-only diagnoses in the determination of risk adjustment for Medicare Advantage plans, and for other purposes.
* H.R. 2608, the Ensuring Seniors Access to Local Pharmacies Act of 2021.
* H.R. 2846, the Ensuring Access to Lower-Cost Medicines for Seniors Act of 2021.
* H.R. 3554/S. 1909, the Pharmacy DIR Reform To Reduce Senior Drug Costs Act.
* H.R. 4074 - To expand the availability of supplemental benefits to certain Medicare Advantage enrollees.
* H.R.3173, the Improving Seniors Timely Access to Care Act of 2021
* Issues related to Pharmacy Direct and Indirect Remuneration (DIR).
* Policies that impact public programs payments for high cost drugs including gene therapies.
* Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kristin |
Julason Damato |
|
|
|
Chris |
Davis |
|
|
|
Gary |
Kline |
|
|
|
Courtney |
Lawrence |
|
|
|
Brendan |
Devine |
|
|
|
Jaymi |
Light |
|
Staff Assistant, Rep. Todd Young; Legislative Correspondent/Press Assistant, Rep. Todd Young; Legislative Assistant, Rep. Todd Young; Legislative Assistant, U.S. Senator Todd Young; Health Policy Director, U.S. Senator Todd Young |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
* Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act.
* Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021.
* Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021.
* Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021
* Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021.
* Issues related to S.909, The Prescription Drug Price Relief Act; S. 908, The Medicare Drug Price Negotiation Act; and S. 920, The Affordable and Safe Prescription Drug Importation Act.
* Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021.
* Issues related to the administration of the 340B drug pricing program
* Issues related to the drug and medical device supply chain concerns related to the coronavirus response efforts.
* Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions.
* Issues retated to H.R. 19/S. 2164, the Lower Costs, More Cures Act.
* July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay.
* June 24, 2019 Executive Order, "Improving Price and Quality Transparency in American Healthcare to Put Patients First".
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kristin |
Julason Damato |
|
|
|
Brendan |
Devine |
|
|
|
Jill |
Canino Kaleta |
|
|
|
Courtney |
Lawrence |
|
|
|
Chris |
Davis |
|
|
|
Gary |
Kline |
|
|
|
Jaymi |
Light |
|
Staff Assistant, Rep. Todd Young; Legislative Correspondent/Press Assistant, Rep. Todd Young; Legislative Assistant, Rep. Todd Young; Legislative Assistant, U.S. Senator Todd Young; Health Policy Director, U.S. Senator Todd Young |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code DEF
16. Specific lobbying issues
* Pharmacy issues related to TRICARE and H.R. 4350 the National Defense Authorization Act (NDAA) for Fiscal Year 2022.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Gary |
Kline |
|
|
|
Chris |
Davis |
|
|
|
Brendan |
Devine |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
Express Scripts, Inc. |
|
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |